Company Overview of FASgen, Inc.
FASgen, Inc. develops, produces, and commercializes small molecule therapeutics and diagnostics using fatty acid biosynthesis targets. The company focuses on creating treatments for cancer, tuberculosis, infectious diseases, and other serious widespread diseases; and metabolic disorders, such as obesity and diabetes. Its product portfolio includes FAS-detect IHC, a monoclonal antibody specific for fatty acid synthase (FAS); and FAS-detect ELISA, a quantitative enzyme-linked immunosorbent assay for the detection of FAS in human serum. The company was founded in 1999 and is based in Baltimore, Maryland.
Bayview Medical Campus
5210 Eastern Avenue
Baltimore, MD 21224
Founded in 1999
Key Executives for FASgen, Inc.
Similar Private Companies By Industry
|Stiefel Laboratories, Inc.||United States|
|Equi-Tox, Inc.||United States|
|Simply H, LLC||United States|
|Organic Science, Inc.||United States|
|Comsort, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact FASgen, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.